[go: up one dir, main page]

BG102812A - SOLID DOSED OUT FORM OF CISAPRID HAVING IMMEDIATE RELEASE INDEPENDENT OF pH - Google Patents

SOLID DOSED OUT FORM OF CISAPRID HAVING IMMEDIATE RELEASE INDEPENDENT OF pH

Info

Publication number
BG102812A
BG102812A BG102812A BG10281298A BG102812A BG 102812 A BG102812 A BG 102812A BG 102812 A BG102812 A BG 102812A BG 10281298 A BG10281298 A BG 10281298A BG 102812 A BG102812 A BG 102812A
Authority
BG
Bulgaria
Prior art keywords
cisaprid
out form
immediate release
dosed out
release independent
Prior art date
Application number
BG102812A
Other languages
Bulgarian (bg)
English (en)
Inventor
Paul Gilis
Guido SMANS
Guido GIJS
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of BG102812A publication Critical patent/BG102812A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BG102812A 1996-04-23 1998-10-01 SOLID DOSED OUT FORM OF CISAPRID HAVING IMMEDIATE RELEASE INDEPENDENT OF pH BG102812A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP96201078 1996-04-23
PCT/EP1997/001462 WO1997039744A1 (en) 1996-04-23 1997-03-20 Immediate release ph-independent solid dosage form of cisapride

Publications (1)

Publication Number Publication Date
BG102812A true BG102812A (en) 1999-05-31

Family

ID=8223900

Family Applications (1)

Application Number Title Priority Date Filing Date
BG102812A BG102812A (en) 1996-04-23 1998-10-01 SOLID DOSED OUT FORM OF CISAPRID HAVING IMMEDIATE RELEASE INDEPENDENT OF pH

Country Status (23)

Country Link
US (1) US6030988A (xx)
JP (1) JPH10510559A (xx)
KR (1) KR100204115B1 (xx)
CN (1) CN1216467A (xx)
AR (1) AR006790A1 (xx)
AT (1) ATE220543T1 (xx)
AU (1) AU720582B2 (xx)
BG (1) BG102812A (xx)
BR (1) BR9708585A (xx)
CA (1) CA2201264C (xx)
CZ (1) CZ332598A3 (xx)
DE (1) DE69713948D1 (xx)
EA (1) EA000804B1 (xx)
EE (1) EE03552B1 (xx)
ID (1) ID16666A (xx)
IL (1) IL125979A0 (xx)
NO (1) NO984016L (xx)
NZ (1) NZ331705A (xx)
PL (1) PL328917A1 (xx)
SK (1) SK144698A3 (xx)
TR (1) TR199802139T2 (xx)
WO (1) WO1997039744A1 (xx)
ZA (1) ZA973449B (xx)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US20030138485A1 (en) * 1998-01-14 2003-07-24 Daiichi Pharmaceutical Co., Ltd. Disintegrant
WO1999053918A1 (en) * 1998-04-20 1999-10-28 Eisai Co., Ltd. Stabilized compositions containing benzimidazole-type compounds
TW407058B (en) * 1998-07-17 2000-10-01 Dev Center Biotechnology Oral cisapride dosage forms with an extended duration
US6353005B1 (en) * 1999-03-02 2002-03-05 Sepracor, Inc. Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist
WO2001028559A1 (en) 1999-10-20 2001-04-26 Eisai Co., Ltd. Method for stabilizing benzimidazole compounds
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
SE0100200D0 (sv) * 2001-01-24 2001-01-24 Astrazeneca Ab New film coating
US7714006B1 (en) 2001-12-03 2010-05-11 King Pharmaceuticals Research & Development, Inc. Methods of modifying the bioavailability of metaxalone
US6407128B1 (en) 2001-12-03 2002-06-18 Elan Pharmaceuticals, Inc. Method for increasing the bioavailability of metaxalone
DE10164510A1 (de) * 2001-12-20 2003-07-10 Schering Ag Orale Fludara reinst Formulierung mit schneller Freisetzung des Wirkstoffes
EP1321142A1 (en) * 2001-12-21 2003-06-25 Novartis AG Solid pharmaceutical composition for oral administration of Tegaserod
HRP20020124A2 (en) * 2002-02-11 2003-10-31 Pliva D D Sustained/controlled release solid formulation as a novel drug delivery system with reduced risk of dose dumping
GB2390541A (en) * 2002-07-12 2004-01-14 Reckitt Benckiser Healthcare Medicinal composition comprising fibre or saccharide bulking agents
WO2004019937A1 (en) * 2002-09-02 2004-03-11 Sun Pharmaceutical Industries Limited Pharmaceutical composition of metaxalone with enhanced oral bioavailability
US20050220870A1 (en) * 2003-02-20 2005-10-06 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
AR045061A1 (es) * 2003-07-18 2005-10-12 Santarus Inc Formulacion farmaceutica y metodo para tratar trastornos gastrointestinales causados por acido
US8993599B2 (en) * 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
TWI398273B (zh) * 2003-07-18 2013-06-11 Santarus Inc 用於抑制酸分泌之醫藥調配物及其製備及使用之方法
US20070292498A1 (en) * 2003-11-05 2007-12-20 Warren Hall Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
US8138204B2 (en) * 2004-01-07 2012-03-20 Aryx Therapeutics, Inc. Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
US8524736B2 (en) 2004-01-07 2013-09-03 Armetheon, Inc. Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
CA2554271A1 (en) * 2004-02-10 2005-08-25 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory agent
CA2561700A1 (en) * 2004-04-16 2005-12-15 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and prokinetic agent
US8906940B2 (en) * 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) * 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8022053B2 (en) * 2004-11-02 2011-09-20 Bayer Schering Pharma Aktiengesellschaft Oral solid dosage forms containing a low dose of estradiol
AU2006249349B2 (en) * 2005-05-26 2012-01-12 Teva Women's Health, Inc. Oral dosage forms comprising progesterone and methods of making and using the same
CN1935264B (zh) * 2005-09-23 2010-05-05 北京德众万全医药科技有限公司 一种用于缓控释片的含有hpmc的新型复合辅料
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
TW200843802A (en) * 2007-02-09 2008-11-16 Drugtech Corp Compositions for improving gastrointestinal nutrient and drug absorption
CN104352465B (zh) * 2014-11-17 2017-04-12 成都新恒创药业有限公司 一种不含二氧化硅的琥珀酸普芦卡必利药物组合物及其制备方法
MX2021000403A (es) 2018-07-12 2021-03-25 Sichuan Haisco Pharmaceutical Co Ltd Composicion de derivados de aminoacido gamma triciclico fusionados y la preparacion de la misma.
CN109394711A (zh) * 2018-11-06 2019-03-01 威海贯标信息科技有限公司 一种酒石酸西尼必利片组合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4962115A (en) * 1981-10-01 1990-10-09 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives
CA2139638A1 (en) * 1992-07-07 1994-01-20 Nancy M. Gray Methods of using (-) cisapride for the treatment of gastro-esophageal reflux disease and other disorders
JPH08502031A (ja) * 1992-07-07 1996-03-05 セプラコア インコーポレーテッド 胃食道逆流疾患およびその他の障害を治療するために▲（＋）▼シサプリドを使用する方法
EP0707492A1 (en) * 1993-07-06 1996-04-24 Merck & Co. Inc. H 2? antagonist-gastrointestinal motility agent combinations
EP0670160B1 (en) * 1994-03-01 1999-07-14 Gerhard Dr. Gergely Granular product or tablet containing an effervescent system and an active pharmaceutical substance, as well as a method for its preparation
CH686865A5 (de) * 1994-06-15 1996-07-31 Gergely Gerhard Pharmazeutische Zubereitung mit einem hydrophoben Wirkstoff und einem Brausesystem, sowie Verfahren zur Herstellung der Zubereitung.
ZA959221B (en) * 1994-11-02 1997-04-30 Janssen Pharmaceutica Nv Cisapride extended release

Also Published As

Publication number Publication date
ID16666A (id) 1997-10-30
BR9708585A (pt) 1999-08-03
NO984016D0 (no) 1998-09-01
IL125979A0 (en) 1999-04-11
WO1997039744A1 (en) 1997-10-30
US6030988A (en) 2000-02-29
EE9800269A (et) 1999-02-15
CA2201264C (en) 1999-08-10
CN1216467A (zh) 1999-05-12
EA199800861A1 (ru) 1999-02-25
EA000804B1 (ru) 2000-04-24
EE03552B1 (et) 2001-12-17
AR006790A1 (es) 1999-09-29
ZA973449B (en) 1998-10-22
KR970069038A (ko) 1997-11-07
ATE220543T1 (de) 2002-08-15
JPH10510559A (ja) 1998-10-13
AU2290497A (en) 1997-11-12
NO984016L (no) 1998-12-23
NZ331705A (en) 1999-11-29
CZ332598A3 (cs) 1999-01-13
CA2201264A1 (en) 1997-10-23
DE69713948D1 (de) 2002-08-22
SK144698A3 (en) 1999-05-07
AU720582B2 (en) 2000-06-08
PL328917A1 (en) 1999-03-01
KR100204115B1 (ko) 1999-06-15
TR199802139T2 (xx) 1999-03-22

Similar Documents

Publication Publication Date Title
BG102812A (en) SOLID DOSED OUT FORM OF CISAPRID HAVING IMMEDIATE RELEASE INDEPENDENT OF pH
DE69924141D1 (de) Orale verabreichung von laktobacillus zur behandlung und prävention von urogenitalen infektionen
ATE337780T1 (de) Indoly-lsulphonyl-verbindungen zur behandlung von störungen des zns
TW252038B (xx)
DE60038038D1 (en) Phosphonatverbindungen
BG102726A (en) Combined therapy for osteoporosis
GR970300016T1 (en) Lactobacillus strains of human origin, their compositions and uses thereof
TR200101103T2 (tr) CGMP PDE-İnhibitörü içeren kontrollu serbest bırakılan farmasötik formülasyonlar
PL338676A1 (en) Sour beverage
EP0417721A3 (en) Novel peptidase and isomerase inhibitors
BG101966A (en) Application of 1l-agonist for the treatment of lack of urine retention
IL140419A0 (en) Novel form of irbesartan, methods for obtaining said form and pharmaceutical compositions containing same
NZ521516A (en) Nutritional mineral fortification of milk by adding an orthophosphate and either a soluble calcium or other nutritional mineral
MXPA03010549A (es) Formas de dosificacion de oxcarbazepina.
DE69827684D1 (de) Neue Lactobazillus-Stämme zur Behandlung von Störungen des Gastrointestinaltraktes
BG102818A (en) D-manitol and method for its preparation
HUT40331A (en) Process for preparing pharmaceutical compositions containing a combination of dihidro-pyridines and ace-inhibitors
MXPA02001373A (es) Utilizacion de agentes antagonistas del cgrp en inhbidores de la liberacion del cgrp para combatir sofocos menopausicos..
IL126235A0 (en) Compounds with growth hormone releasing properties
CA2284142A1 (en) Compositions containing lysophosphotidic acids which inhibit apoptosis and uses thereof
TR200101366T2 (tr) Farmasötik kompozisyonların muhtevasında bulunan bazı substitüte kaprolaktamlar ve tümör tedavisinde kullanımları.
PT1353681E (pt) ''bifidobactérias capazes de evitar a diarreia''
DE69715644D1 (de) VERWENDUNGEN VON alpha-LACTALBUMIN ZUSAMMENSETZUNGEN
BG104292A (en) Methods and compositions for the treatment of rheumatoid arthritis
IL140044A0 (en) Compounds with growth hormone releasing properties